Kim Hunter-Schaedle, PhD, Chief Scientific Officer of the Children’s Tumor Foundation, discusses therapeutic options for neurofibromatosis and their progression from surgery, chemotherapy or bracing/amputation to targeted drug treatments.

Summary:
Improved therapeutic options for neurofibromatosis over the past few years mean that traditional surgery, chemotherapy and bracing or amputation are being replaced by targeted drugs that can treat benign tumors. Clinical trials are currently underway involving drugs such as rapamycin and sorafenib.

For more information, please visit:
CTF

Sponsored by The Doctor’s Channel